Patents Assigned to Neurovance, Inc.
  • NOVEL METHODS
    Publication number: 20160303076
    Abstract: Provided are novel methods comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to a patient in need thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: October 20, 2016
    Applicant: Neurovance, Inc.
    Inventors: Anthony MCKINNEY, Frank GENTILE, Timothy HSU, Franklin BYMASTER, Walter PISKORSKI, Richard WELTER
  • 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
    Patent number: 9205074
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: December 8, 2015
    Assignee: Neurovance, Inc.
    Inventors: Phil Skolnick, Anthony Basile, Zhengming Chen, Joseph W. Epstein
  • 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
    Patent number: 8877798
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Grant
    Filed: May 5, 2013
    Date of Patent: November 4, 2014
    Assignee: Neurovance, Inc.
    Inventors: Phil Skolnick, Anthony Basile, Zhengming Chen, Joseph W. Epstein
  • Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
    Publication number: 20140206740
    Abstract: The present invention relates to (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.
    Type: Application
    Filed: June 2, 2013
    Publication date: July 24, 2014
    Applicant: Neurovance, Inc.
    Inventors: Anthony Alexander McKINNEY, Frank Bymaster